Recent 8-K filings for BLLN

• May 6, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  BillionToOne Q1 revenue $108.4M (+84% YoY), raises FY 2026 guidance to $450M-$465M

  Net income $18.0M ($0.34 diluted) vs loss of $4.0M (-$0.39) in Q1 2025.

• March 4, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 5.02item 9.01 ◈ Earnings Releases ×2

  BillionToOne Q4 rev $96.1M (+113% YoY); net income $4.4M; raises FY26 guidance

  Q4 revenue $96.1M (+113% YoY); net income $4.4M ($0.11 diluted) vs loss of $11.5M.

• January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  BillionToOne guides FY2026 revenue $415-430M, up ~43% YoY; positive operating income

  Reiterated FY2025 revenue guidance of $293M-$299M with positive GAAP operating income.

• December 9, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 5.02item 9.01

  BillionToOne Q3 revenue $83.5M (+117% YoY); guides FY2025 revenue $293-299M

  Q3 total revenue $83.5M (+117% YoY); prenatal revenue $74.1M (+102%), oncology $8.7M (7.6x YoY).

• November 10, 2025, 6:59 PM ET other material materiality 0.75 positive item 5.03item 8.01item 9.01 ◈ Governance Changes ×2

  BillionToOne closes IPO of 5.23M shares at $60; gross proceeds ~$314M

  Closed IPO on Nov 7, 2025, selling 5,233,765 shares (including full underwriter option) at $60.00 per share.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.80 · Most common event earnings

5 positive 0 negative 0 neutral

source · BLLN on sec.gov